The study endpoints were Thrombolysis In Myocardial Infarction (TIMI) flow and TIMI Myocardial Perfusion (TMP) grade improvement, major adverse cardiac event (MACE) rate of death, MI, repeat intervention and bleeding at 1 and 6 months. Results: There were 120 and 75 patients in regime A and B respectively.